DAFNA Capital Management LLC 13F holdings
DAFNA Capital Management LLC reported 88 positions with a total reported value of $524.4M as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-14. Top holdings by reported value: RVMD REVOLUTION MEDICINES INC (20.1%), SPDR S&P BIOTECH ETF (5.9%), CMPS COMPASS PATHWAYS PLC (5.4%), STXS STEREOTAXIS INC (4.5%), NKTR NEKTAR THERAPEUTICS (4.2%). Against 2026-03-31 it opened 16 new positions and exited 10. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.
Email me when DAFNA Capital Management LLC files its 13F
A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.
Top holdings
25 largest of 88 positions · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| RVMD REVOLUTION MEDICINES INC | 562,630 | $105.4M | 20.1% |
| SPDR S&P BIOTECH ETF | 196,505 | $31.1M | 5.9% |
| CMPS COMPASS PATHWAYS PLC | 2,011,952 | $28.5M | 5.4% |
| STXS STEREOTAXIS INC | 13,680,554 | $23.5M | 4.5% |
| NKTR NEKTAR THERAPEUTICS | 318,380 | $22.2M | 4.2% |
| DNLI DENALI THERAPEUTICS INC | 739,014 | $19.0M | 3.6% |
| IDYA IDEAYA BIOSCIENCES INC | 497,240 | $18.5M | 3.5% |
| ATRC ATRICURE INC | 597,431 | $16.7M | 3.2% |
| XENE XENON PHARMACEUTICALS INC | 250,772 | $15.1M | 2.9% |
| CYTK CYTOKINETICS INC | 171,998 | $14.7M | 2.8% |
| RCUS ARCUS BIOSCIENCES INC | 441,829 | $13.6M | 2.6% |
| ASND ASCENDIS PHARMA A/S | 48,469 | $12.9M | 2.5% |
| NBIX NEUROCRINE BIOSCIENCES INC | 57,769 | $9.7M | 1.9% |
| AXGN AXOGEN INC | 208,960 | $9.7M | 1.8% |
| PODD INSULET CORP | 61,870 | $9.4M | 1.8% |
| EWTX EDGEWISE THERAPEUTICS INC | 226,819 | $9.2M | 1.8% |
| BCAX BICARA THERAPEUTICS INC | 284,955 | $8.5M | 1.6% |
| ISHARES NASDAQ BIOTECH INDX | 42,595 | $8.1M | 1.5% |
| SNDX SYNDAX PHARMACEUTICALS INC | 335,255 | $7.3M | 1.4% |
| MPLT MAPLIGHT THERAPEUTICS INC | 171,006 | $6.1M | 1.2% |
| LRMR LARIMAR THERAPEUTICS INC | 2,008,164 | $6.1M | 1.2% |
| IPSC CENTURY THERAPEUTICS INC | 2,400,458 | $5.9M | 1.1% |
| DXCM DEXCOM INC | 86,279 | $5.8M | 1.1% |
| IMVT IMMUNOVANT INC | 149,524 | $5.8M | 1.1% |
| INGN INOGEN INC | 845,179 | $5.5M | 1.0% |
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES
New positions this quarter
Held at 2026-06-30, not at 2026-03-31 · 16 in all · reported value as of 2026-06-30
| Holding | Shares | Reported value | % of portfolio |
|---|---|---|---|
| LAKEFRONT BIOTHERAPEUTICS NV | 130,175 | $3.9M | 0.7% |
| KYMR KYMERA THERAPEUTICS INC | 27,000 | $3.1M | 0.6% |
| PROQR THERAPEUTICS NV | 1,530,361 | $2.8M | 0.5% |
| ANL ADLAI NORTYE LTD | 239,553 | $2.8M | 0.5% |
| NGEN NERVGEN PHARMA CORP | 1,050,000 | $2.2M | 0.4% |
| RNA ATRIUM THERAPEUTICS INC | 128,000 | $1.7M | 0.3% |
| EPRX EUPRAXIA PHARMACEUTICALS INC | 225,600 | $1.5M | 0.3% |
| DSGN DESIGN THERAPEUTICS INC | 102,600 | $1.5M | 0.3% |
| CRBP CORBUS PHARMACEUTICALS HLDGS | 107,773 | $1.0M | 0.2% |
| SPTX SEAPORT THERAPEUTICS INC | 32,400 | $703.7K | 0.1% |
| ARTV ARTIVA BIOTHERAPEUTICS INC | 67,101 | $650.9K | 0.1% |
| EDIT EDITAS MEDICINE INC | 170,470 | $552.3K | 0.1% |
| QTTB Q32 BIO INC | 32,896 | $419.1K | <0.1% |
| NVCT NUVECTIS PHARMA INC | 20,000 | $367.8K | <0.1% |
| TNYA TENAYA THERAPEUTICS INC | 300,000 | $221.7K | <0.1% |
| KARD KARDIGAN INC | 5,000 | $119.2K | <0.1% |
Sold out
Held at 2026-03-31, gone by 2026-06-30 · 10 in all · reported value as of 2026-03-31
| Holding | Shares 2026-03-31 | Reported value | % of portfolio then |
|---|---|---|---|
| DAY ONE BIOPHARMACEUTICALS I | 978,463 | $21.0M | 4.8% |
| KALVISTA PHARMACEUTICALS INC | 267,402 | $5.4M | 1.2% |
| GALAPAGOS NV | 130,175 | $3.9M | 0.9% |
| PROQR THERAPEUTICS N V | 1,567,561 | $2.5M | 0.6% |
| FULC FULCRUM THERAPEUTICS INC | 205,000 | $1.6M | 0.4% |
| ORIC ORIC PHARMACEUTICALS INC | 98,724 | $945.5K | 0.2% |
| ZBIO ZENAS BIOPHARMA INC | 42,500 | $830.9K | 0.2% |
| NAMS NEWAMSTERDAM PHARMA CO | 20,000 | $640.2K | 0.1% |
| KPTI KARYOPHARM THERAPEUTICS INC | 45,800 | $255.1K | <0.1% |
| NMRA NEUMORA THERAPEUTICS INC | 70,000 | $136.5K | <0.1% |
Biggest increases and decreases
Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30
Increases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| DNLI DENALI THERAPEUTICS INC | 318,500 | 739,014 | +132.0% | $19.0M |
| NKTR NEKTAR THERAPEUTICS | 165,178 | 318,380 | +92.7% | $22.2M |
| PODD INSULET CORP | 10,870 | 61,870 | +469.2% | $9.4M |
| ASND ASCENDIS PHARMA A/S | 23,177 | 48,469 | +109.1% | $12.9M |
| EWTX EDGEWISE THERAPEUTICS INC | 112,236 | 226,819 | +102.1% | $9.2M |
| SNDX SYNDAX PHARMACEUTICALS INC | 217,355 | 335,255 | +54.2% | $7.3M |
| KIDS ORTHOPEDIATRICS CORP | 95,659 | 189,130 | +97.7% | $3.6M |
| ALLO ALLOGENE THERAPEUTICS INC | 1,370,118 | 2,000,000 | +46.0% | $4.2M |
| AQST AQUESTIVE THERAPEUTICS INC | 368,415 | 645,915 | +75.3% | $2.7M |
| ANNX ANNEXON INC | 117,812 | 297,812 | +152.8% | $1.7M |
| NGNE NEUROGENE INC | 56,635 | 89,032 | +57.2% | $2.8M |
| MAZE MAZE THERAPEUTICS INC | 35,000 | 65,000 | +85.7% | $1.9M |
Decreases
| Holding | Shares 2026-03-31 | Shares 2026-06-30 | Change | Reported value |
|---|---|---|---|---|
| SPDR S&P BIOTECH ETF | 318,505 | 196,505 | -38.3% | $31.1M |
| BHVN BIOHAVEN LTD | 845,735 | 137,593 | -83.7% | $2.0M |
| MBX MBX BIOSCIENCES INC | 175,465 | 11,809 | -93.3% | $651.9K |
| CMPS COMPASS PATHWAYS PLC | 2,418,882 | 2,011,952 | -16.8% | $28.5M |
| BCAX BICARA THERAPEUTICS INC | 421,733 | 284,955 | -32.4% | $8.5M |
| CYTK CYTOKINETICS INC | 217,497 | 171,998 | -20.9% | $14.7M |
| SCYX SCYNEXIS INC | 1,086,956 | 135,868 | -87.5% | $553.0K |
| ISHARES NASDAQ BIOTECH INDX | 62,095 | 42,595 | -31.4% | $8.1M |
| RVMD REVOLUTION MEDICINES INC | 580,678 | 562,630 | -3.1% | $105.4M |
| NBIX NEUROCRINE BIOSCIENCES INC | 70,615 | 57,769 | -18.2% | $9.7M |
| ALKS ALKERMES PLC | 139,482 | 101,266 | -27.4% | $5.3M |
| AXGN AXOGEN INC | 249,960 | 208,960 | -16.4% | $9.7M |
CIK 1389933 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY
